ReviewOncogene2006
Cell growth control: little eukaryotes make big contributions.
Review in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 218 citations in OpenAlex.
- Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin inJAC-antimicrobial resistance · 2026Article
- Mechanisms and Strategies for Engineering Oxidative Stress Resistance inChem & bio engineering · 2025Review
- Perspectives on current and future yeast technologies for ethanol-based biofuels and bioproducts.FEMS yeast research · 2025Review
- Translation regulation in response to stress.The FEBS journal · 2024Review
- Hydrogen peroxide modulates the expression of the target of rapamycin (TOR) and cell division in Arabidopsis thaliana.Protoplasma · 2024Article
- The dual life of disordered lysine-rich domains of snoRNPs in rRNA modification and nucleolar compaction.Nature communications · 2024Article
- The Ubiquitous Wilt-Inducing PathogenPathogens (Basel, Switzerland) · 2024Review
- Mitochondria complex I deficiency in Candida albicans arrests the cell cycle at S phase through suppressive TOR and PKA pathways.FEMS yeast research · 2024Article
- Pleiotropy drives evolutionary repair of the responsiveness of polarized cell growth to environmental cues.Frontiers in microbiology · 2023Article
- Deciphering the function and evolution of the target of rapamycin signaling pathway in microalgae.Journal of experimental botany · 2022Article
- TORC1 and PKA activity towards ribosome biogenesis oscillates in synchrony with the budding yeast cell cycle.Journal of cell science · 2022Article
- Target of Rapamycin Signaling Involved in the Regulation of Photosynthesis and Cellular Metabolism inInternational journal of molecular sciences · 2022Article
- Salicylic acid fights against Fusarium wilt by inhibiting target of rapamycin signaling pathway in Fusarium oxysporum.Journal of advanced research · 2022Article
- Interaction of TOR and PKA Signaling inBiomolecules · 2022Review
- Robust Cre recombinase activity in the biotrophic smut fungus Ustilago maydis enables efficient conditional null mutants in planta.Genetics · 2022Article
- Modeling and analysis of the macronutrient signaling network in budding yeast.Molecular biology of the cell · 2021Article
- Target of rapamycin controls hyphal growth and pathogenicity through FoTIP4 in Fusarium oxysporum.Molecular plant pathology · 2021Article
- The TOR-dependent phosphoproteome and regulation of cellular protein synthesis.The EMBO journal · 2021Article
- Cellular quiescence in budding yeast.Yeast (Chichester, England) · 2021Review
- TOR Inhibitors Synergistically Suppress the Growth and Development ofFrontiers in microbiology · 2021Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The story of rapamycin is a pharmaceutical fairytale. Discovered as an antifungal activity in a soil sample collected on Easter Island, this macrocyclic lactone and its derivatives are now billion dollar drugs, used in, and being evaluated for, a number of clinical applications. Taking advantage of its antifungal property, the molecular Target Of Rapamycin, TOR, was first described in the budding yeast Saccharomyces cerevisiae. TORs encode large, Ser/Thr protein kinases that reside in two distinct, structurally and functionally conserved, multi-protein complexes. In yeast, these complexes coordinate many different aspects of cell growth. TOR complex 1, TORC1, promotes protein synthesis and other anabolic processes, while inhibiting macroautophagy and other catabolic and stress-response processes. TORC2 primarily regulates cell polarity, although additional readouts of this complex are beginning to be characterized. TORC1 appears to be activated by nutrient cues and inhibited by stresses and rapamycin; however, detailed mechanisms are not known. In contrast, TORC2 is insensitive to rapamycin and physiological regulators of this complex have yet to be defined. Given the unsurpassed resources available to yeast researchers, this simple eukaryote continues to contribute to our understanding of eukaryotic cell growth in general and TOR function in particular.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.